We evaluated the effect of hapten heterology on free thyroxine (FT4) immunoassays involving the biotinstreptavidin system and time-resolved fluorometry. We compared protein derivatives of thyroxine (T4) and tniodothyronine (T3) as solid-phase antigen or biotinylated protein-tracer conjugate for competitive (or sequential) binding to a mouse anti-I4 monoclonal antibody. In both one-and two-step assays, the heterologous combination of the antibody and T3 conjugates showed superior standard curve sensitivity but up to eightfold lower zero standard signal (B0) when the same amounts of antibody and conjugates were used. The improved sensitivitywas not altered when the amount of coupled 13 was increased to obtain a B0 value similar to that of the homologous combination of antibody and T4 conjugates. In the twoCyberFluor Inc., 179 JohnSt., Toronto, Ontario, Canada M5T
cation of thyroid disorders (1). In assays of labeled antigen, the tracer used to monitor the reaction is synthesized by conjugating the analyte to a reporter molecule either directly or indirectly through an intermediate complementary interaction, such as the biotinstreptavidin system (2, 3). When the assay design involves labeled antibody as the tracer, the antigen is conjugated to a carrier molecule before immobilization (2) (3) (4) . The process of cross-linking the analyte to a different and often much larger molecule may lead to a substantially increased antibody-conjugate binding affinity, which may compromise the establishment of appropriate standard curve characteristics. The problem of preferential binding of the antibody to the tracer may be more troublesome in two-step assay formats, in which the tracer could readily displace antibody-bound analyte during the back-titration step, even though the reaction would proceed at a significantly lower temperature and for less time than the immunoreaction step.
Combining the antibody with a tracer-conjugate derivative that has a slightly different structure than the immunogen against which the antibody was raised has been described as an effective means of reducing the enhanced binding affinity of the antibody-conjugate interaction. The three types of structural heterologies that were identified-bridge, site, and hapten-were shown to improve assay sensitivity with little or no adverse effect on specificity (5) . Hapten heterology, separately or combined with the other types of heterology, has been successfully applied in the design of various enzymatic, nephelometric, and luminescent immunoassays (5) (6) (7) (8) . Development of the one-step labeledanalog free thyroxine (FF) assay was also based on the use of a structurally altered tracer molecule.' In this case the structural alteration was to reduce tracer interaction with serum thyroxine (T4)-binding proteins without significantly affecting binding to anti-T4 antibodies (9).
We reported a one-step labeled-antibody assay for FL in serum comprising the biotin-streptavidun system and time-resolved fluorometry (4) and more recently proposed application of anti-T4 antibodies in combination with triiodothyronine (T3)-protein conjugates as an ideal approach to the development of an FF4 immunoassay (10). We reasoned that, because of the lower binding affinity of the anti-T4 antibody for T3, the haptenheterologous combination should substantially improve the overall standard-curve characteristics while minimizing the interfering effect of thyroid-hormone-binding proteins. Our assumption, largely theoretical, for the latter is that T3 does not bind to T4-binding prealburnin (11) and that the affinity of the abnormally increased albumin subfraction in familial dysalbuminemic hyperthyroxinemia (FDH), relative to the bulk of 'Nonstandard abbreviations: F1, free thyroxine; T4,thyroxine; T3, triiodothyronine; FDH, familial dysalbuminemic hyperthyroxinemia; TBG, thyroxine-binding globulin; BCPDA,4,7-bis(chlorosulfophenyl)-1,1O-phenanthroline-2,9-dicarboxylic acid; BGG, bovine y-globulin; NHS-LC-biotin, sulfosuccinimidyl 6-(biotinamido) hexanoate; and NHS, N-hydroxysuccinimide.
albumin, for binding to T3 is unchanged, whereas its binding to T4 is substantially increased (1). Although both thyroxine-binding globulin (TBG) and serum albumin bind T3 with -10-fold lower affinity than T4 (11), the difference may not be important because the anti-T4 antibodies also bind P3 much less efficiently.
Here we present our preliminary evaluation of the effect of hapten heterology and discuss the potential advantages of this approach in improving the performance of both one-step and two-step FT4 assays. 
Materials and Methods

Buffers and standards.
The assay buffer was 50 mmolJL Tris buffer, pH 7.0, containing 9 g of NaCl, 0.5 g of sodium azide, and 1 g of bovine serum albumin per liter. The immunocomplex dissociation solution (reading solution) was 5.0 mmol/L Tris buffer, pH 7.4, containing 2.9 g of NaCl, 0.5 mL of Tween 20 [polyoxyethylene (20) sorbitan monolaurate], and -37 rnL of Tergitol 4 per liter. The composition of the coating, blocking, and streptavidin-thyroglobulin-4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA) dilution buffers and wash solution were as described previously (12) . The Fr4 standards in the range of 0 to -71 pmol/L were from the FIAgenTh Fr4 Kit (CyberFluor Inc.). The standards were prepared in resinstripped human serum (Scantibodies Lab., Santee, CA) containing 0.5 g/L sodium azide as preservative.
Monoclonal
antibody.
The anti-T4 monoclonal antibody, supplied by CyberFluor Inc., was raised against T4 coupled to bovine serum albumin by using the watersoluble carbodiimide method (13) . The relative affinity of the antibody for binding to T, T4, and their bridgeheterologous bovine y-globulin (BGG) conjugates (see below) was determined from the cross-reactivity in the FlAgen total T4 assay (CyberFluor Inc.) at 50% displacement of the maximum binding of the tracer. The conjugation ratio of T3 and T4 to the carrier protein was derived spectrophotometrically (12) by using the molar absorptivity of BGG, T3, and T4 at 280 nm and the protein concentration of the conjugates. The estimated relative affinities (cross-reactivities) of the antibody for T3, T4, T3-BGG, and T4-BGG were 4.2, 100, 6.5, and 170, respectively. We prepared a 2 g/L (-12.5 moIJL) solution of BGG in 0.2 mol/L Na2CO3 buffer, pH 9.1, and dialyzed it overnight against several changes of the same buffer. To 4 mg of the protein (-25 nmol) in 2 mL, we then added various amounts of NHS-T4 or NHS-T3 dissolved in 100 L of dimethyl sulfoxide. We usedbetween 1 and 20 activated hormone molecules per BGG molecule. The incubation proceeded for 1 h at room temperature, and the mixtures were then dialyzed extensively against 0.05 mol/L NaHCO3 buffer, pH 8, containing 9 g of NaCI and 0. For biotinylation of the conjugates, we added to 1 mg (1 mL) of each conjugate 300 zL of 1 moIIL Na2CO3 buffer, pH 9.1, and 50 L of dimethyl sulfoxide containing 1 mg of NHS-LC-biotin; after 1 h incubation at room temperature, we dialyzed the reaction mixture against 0.05 mol/L NaHCO3 buffer, pH 8, containing 9 g of NaCl and 0.5 g of sodium azide per liter and adjusted the conjugate concentration to 0.5 g/L (15) . Under these conditions, the conjugates are stable for 12 months at 4 #{176}C. We used the same protocolto biotinylate the anti-P4 antibody (1 g/L). After dialysis, the stock biotinylated antibody solution was stored at 4#{176}C.
Preparation of the detection reagent (streptauidin-
thymglobulin-BCPDA-Eu).
The synthesis and characterization of the streptavidin-based macromolecular complex labeled with the europium chelator BCPDA were detailed elsewhere (16, 17) . The detection reagent was diluted 50-fold into the streptavidin-thyroglobulin-BCPDA dilution buffer to yield a 4.4 nmol/L working solution of streptavidin.
Assay Protocol
One-step FT4 assay. The one-step labeled-antibody assay protocol (Figure IA) in microtiter-well format was as described previously (4) except that the fluorescence measurement was performed by liquid-phase fluorometry as briefly described below and detailed previously (18). The coating concentration of the various conjugates ranged from 100 to 1000 ng/well. Each conjugate was tested against 30-125 fmol of the biotinylated mouse anti-T4 monoclonal antibody in 100 pL of the assay buffer per well. In performing the one-step labeled-antigen assay (Figure 1B) Two-step FT4 assay. The design of the two-step assay in wells coated with goat anti-mouse antibody ( Figure  1C ) was similar to that of the one-step labeled-antigen assay except that the samples (10 L) were first incubated with -300' fmol of the anti-P4 monoclonal antibody in 100 L of the assay buffer, and the wells were incubated for 1 h at room temperature as described above. After four washes, we added -'100 ng of the biotinylated P3-or T4-BGG per well (NHS-P4 and NHS-T3 conjugation ratios were 1.5 and 5 molecules per BGG molecule, respectively) in 100 pL of the assay buffer and incubated for 15 or 30 mm at 4#{176}C, room temperature, or 37#{176}C. The wells were then washed four times and processed as described above.
T4 displacement
experiments.
To perform the analyte displacement experiments,
we added 75 fmol of the anti-P4 antibody and 0.65 nmol of native P4, each in 50 1i,L of the assay buffer, into wells coated with goat anti-mouse antibody and incubated the wells for 1 h at room temperature. After four washes, we added, in triplicate, 500 ng/well of biotinylated P3-or T4-BGG (both labeled at the ratio of 5 molecules of activated hormone per globulin molecule) and incubated for 5-120 miii at 4#{176}C, room temperature, or 37#{176}C. The wells were then washed four times and processed as described above. The percent displacement was determined by dividing the mean fluorescence signal generated at intervals by the mean signal of the control wells, which were processed as above but were not pretreated with T4. We incubated the control wells for the maxiznuni incubation time (120 mm) at the appropriate temperature.
Results and DiscussIon
One-Step Fr4 Assay
In the one-step labeled-antibody assay ( Figure IA) , we evaluated plates coated with different amounts of BGG (100-1000 ng/well) labeled under identical conditions with increasing molar ratios of activated P4 or P3 derivatives (-1-20 molecules of NHS-T4 or NHS-P3 per protein molecule) for competitive binding to various dilutions of the biotinylated anti-P4 antibody (3 1-125 fmol/100 ML in each well). For similar conjugate and antibody concentrations, the heterologous combination of the antibody with P3-BGG conjugate gave as much as an eightfold lower B0 value (the fluorescence response of the zero standard) than did the corresponding homologous assays (T4-BGG conjugate), but the standard curves generated were shifted to substantially lower FF4 concentrations (Figure 2) . The maximum binding signal of the heterologous combination could be increased to approximate that of the homologous assay by increasing the amount of coupled P3 per well relative to that of coupled P4. With a common antibody concentration of -41 fmollwell and T4-BGG conjugate coating concentration of 100 ng (labeled with the activated P4 at -1.5 molecule per protein molecule) and P3-BGG conjugate coating concentration of 500 ng (labeled with the activated P3 at -5 molecules per protein molecule), the heterologous system gave a maximum binding signal similar to that of the homologous system without corn- promising the improved standard-curve sensitivity throughout the assay range (Figure 3) . Assuming similar conjugation and coating efficiency, the required amount of bound P3 per well was -16-fold greater than that of P4 conjugate. In the one-step labeled-antigen configuration ( Figure  1B) , we biotinylated the above conjugates and evaluated them for competitive binding to the anti-P4 monoclonal antibody in microtitration wells coated with a goat anti-mouse antibody. In this configuration, assaysincorporating the combination of the antibody with the biotinylated BGG-P3 were also consistently more sensitive at given antibody and conjugate concentrations. With appropriate selection of conjugate and antibody concentrations, comparable binding characteristics shown above for the labeled antibody assays could be readily duplicated (data not shown).
Two-Step FT4 Assay
In analyte-displacement experiments, we monitored binding kinetics of excessP3-.BGG and P4-BGG derivatives to the anti-P4 antibody (75 fmoIf5O ML in each well) blocked by preincubation with excess P4 (0.65 nmol/50 ML in each well). Consistent with the relative binding affinity of the antibody for P3, P4, P3-BGG, and P4-BGG established by cross-reactivity studies (4.2%, 100%, 6.5% and 170%, respectively), the homologous P4-BGG conjugate displaced -'20-40% of bound P4 during the initial 15-30 mm of incubation at room temperature or 37#{176}C. At 4#{176}C, -'5-10% of the bound P4 was displaced. In contrast, the heterologous T3-BGG conjugate was much less efficient in displacing P4, and <5% of the bound P4 was displaced after 30 nun of incubation at 37 #{176}C (Figure 4) . Similar results were [1] [2] [3] or T3 (curves4-6) conjugates, at 37 'C (curves land 4), room temperature(curves 2and 5), and 4 'C (curves 3and 6) obtained when the antibody was preblocked with the conjugates and the effect of excess P4 in displacing bound conjugate was monitored (data not shown).
The standard curve characteristics of the two-step assay ( Figure 1C ) obtained with the combination of the antibody with the biotinylated T3-BGG and T4-BGG conjugates are shown in Table 1 . Compared with the homologous combination, the standard curves in the heterologous assay were shifted to a lower Fl'4 concentration (5.8-8.9 pmol/L at 50% of maximum binding). The sensitivity of the homologousassaysperformed sinilarly appeared insufficient for routine use (16 to >68 pmol/L at 50% binding), and the best performance was observed with a 15-min second-step incubation at 4#{176}C.
Assay Characteristics
To further investigate the effect of hapten heterology, we evaluated the performance characteristics of the one-step labeled-antibody assay (Figure IA) , using the antibody and coating conjugate concentrations described in Figure 3 . 
Effect of dilution.
A fourfold dilution of patients' specimenswith the assay buffer resulted in a decrease of -60% in Fr4 values estimated by the hapten-heterologous assay (Figure 7 ). When samples with Fr4 concentration of -40 pmol/L were tested by the Clinical Assay two-step RIA, a decrease of -10% and 45% was observed at four-and eightfold dilutions, respectively. However, a dilution effect similar to that of the proposed assay was also observed with the homologous combination of the antibody and immobilized T4-BGG conjugate (data not shown) and was reported by other investigators (19 if not better than that of the homologousassay system. As recently reported for a one-step labeled-antibody Fr4 radioimmunoassay (19) , the reduced binding affinity would also allow incorporation of a much higher molar concentration of the heterologous hapten (T3) per assay well, relative to that of the antibody. This may minimize the adverse effect of thyroid hormone autoantibodies and help speed the reaction kinetics by favoring association of the antibody to the solid-phase antigen (19, 20) .
In addition, because of the lack of binding of T3 to prealbumin (11) and its significantly lower binding affinity for the abnormally increased minor component of serum albumin in FDH (1), the heterologous combination may be less prone to interferences by normal or abnormal fluctuation of these proteins, especially in the one-step format. The results of the correlation studies indicate that the present assay is not affected by a wide variation in the concentrations of human serum albumin and TBG. However, further confirmation of these observations requires comparative analyses of samples from pregnant women and patients with severe nonthyroidal illness. Finally, although the effect of hapten heterology on the two-step assay was not filly investigated, it is highly advantageous that analyte displacement could be minimized or completely prevented. This approach, in addition to improving performance, would also simplify developmental work and procedural requirements, allowing both steps of the assay to be performed at the same temperature. We propose that combining anti-T4 antibodies with T3 conjugate may be advantageous for T4 immunoassay development and for applications where improved sensitivity and reduction of interferences by endogenousbinders may be important.
